Currently, the increased utilization of tumor genomic sequencing in pediatric cancer (which I assume you mean by “more frequent sequencing”) has resulted in more companies and academic practices implementing NGS platforms and on-site sequencing. This increased clinical use leads to an in...

I imagine this answer, as often is the case in the setting of great complexity, is "it depends." Genomic sequencing is far less expensive than it was previously, but it remains rather costly. And, papers such as the one by Summers et al. describe success at identifying "actionable" genomic alteratio...